CytoImmune will participate in the Stifel 2021 Virtual Healthcare Conference

CytoImmune Not Affected by The Recent Challenges in Allogeneic CAR T Cell Engineering
October 17, 2021
CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer
November 10, 2021

Register for the Stifel 2021 Virtual Healthcare Conference

Speaker Ready Practice Session:

Dated: November 15th, 2021

Time: 9:20 AM (ET)

About CytoImmune Therapeutics, Inc.

CytoImmune Therapeutics is a clinical-stage biotechnology company founded in 2017. It is focused on developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of a patient’s own immune system to eliminate cancer cells. CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in hematological and solid malignancies.


Name: Alice Mior
Phone: +57 312 8113601

SOURCE: CytoImmune Therapeutics